Leprosy	B:C0023343
Drug	B:C0013203
Resistance	I:C0013203
Surveillance	B:C0733511
in	O
Colombia	B:C3245499
:	O
The	O
Experience	B:C0596545
of	O
a	O
Sentinel	B:C0454664
Country	I:C0454664
.	O

An	O
active	B:C4290001
search	I:C4290001
for	O
Mycobacterium	B:C0026922
leprae	I:C0026922
drug	B:C0013203
resistance	I:C0013203
was	O
carried	O
out	O
,	O
243	O
multibacillary	B:C1562585
patients	O
from	O
endemic	B:C0017446
regions	I:C0017446
of	O
Colombia	B:C3245499
were	O
included	O
from	O
2004	O
to	O
2013	O
in	O
a	O
surveillance	B:C1515095
program	I:C1515095
.	O

This	O
program	B:C1515095
was	O
a	O
World	B:C0043237
Health	I:C0043237
Organization	I:C0043237
initiative	O
for	O
drug	B:C0013203
resistance	I:C0013203
surveillance	B:C0733511
in	O
leprosy	B:C0023343
,	O
where	O
Colombia	B:C3245499
is	O
a	O
sentinel	B:C0454664
country	I:C0454664
.	O

M.	B:C0026922
leprae	I:C0026922
DNA	B:C0012854
from	O
slit	B:C0444101
skin	I:C0444101
smear	I:C0444101
and	O
/	O
or	O
skin	B:C0586537
biopsy	I:C0586537
samples	I:C0586537
was	O
amplified	B:C0683230
and	O
sequenced	B:C0917792
to	O
identify	O
mutations	B:C0596611
in	O
the	O
drug	B:C0017337
resistance	I:C0017337
determining	I:C0017337
region	I:C0017337
(	O
drug	B:C0017337
resistance	I:C0017337
determining	I:C0017337
region	I:C0017337
)	O
in	O
rpoB	O
,	O
folP1	O
,	O
gyrA	O
,	O
and	O
gyrB	O
,	O
the	O
genes	B:C0017337
responsible	O
for	O
rifampicin	B:C0035608
,	O
dapsone	B:C0010980
and	O
ofloxacin	B:C0028902
drug	B:C0013203
-	I:C0013203
resistance	I:C0013203
,	O
respectively	O
.	O

Three	O
isolates	B:C1764827
exhibited	O
mutations	B:C0596611
in	O
the	O
drug	B:C0017337
resistance	I:C0017337
determining	I:C0017337
region	I:C0017337
rpoB	O
gene	O
(	O
Asp441	B:C0596611
Tyr	I:C0596611
,	O
Ser456	B:C0596611
Leu	I:C0596611
,	O
Ser458	B:C0596611
Met	I:C0596611
)	O
,	O
two	O
in	O
the	O
drug	B:C0017337
resistance	I:C0017337
determining	I:C0017337
region	I:C0017337
fol	O
P1	O
gene	O
(	O
Thr53	B:C0596611
Ala	I:C0596611
,	O
Pro55	B:C0596611
Leu	I:C0596611
)	O
,	O
and	O
one	O
isolate	B:C1764827
exhibited	O
mutations	B:C0596611
in	O
both	O
drug	B:C0017337
resistance	I:C0017337
determining	I:C0017337
region	I:C0017337
rpoB	O
(	O
Ser456	B:C0596611
Met	I:C0596611
)	O
and	O
drug	B:C0017337
resistance	I:C0017337
determining	I:C0017337
region	I:C0017337
folP1	O
(	O
Pro55	B:C0596611
Leu	I:C0596611
)	O
,	O
suggesting	O
multidrug	O
resistance	O
.	O

One	O
isolate	B:C1764827
had	O
a	O
double	O
mutation	B:C0596611
in	O
folP1	O
(	O
Thr53	B:C0596611
Ala	I:C0596611
and	O
Thr88	B:C0596611
Pro	I:C0596611
)	O
.	O

Also	O
,	O
we	O
detected	B:C0442726
mutations	B:C0596611
outside	O
of	O
drug	B:C0017337
resistance	I:C0017337
determining	I:C0017337
region	I:C0017337
that	O
required	O
in	B:C1515655
vivo	I:C1515655
evaluation	B:C0220825
of	O
their	O
association	O
or	O
not	O
with	O
drug	B:C0013203
resistance	I:C0013203
:	O
rpoB	O
Arg505	B:C0596611
Trp	I:C0596611
,	O
folP1	O
Asp91	B:C0596611
His	I:C0596611
,	O
Arg94	B:C0596611
Trp	I:C0596611
,	O
and	O
Thr88	B:C0596611
Pro	I:C0596611
,	O
and	O
gyrA	O
Ala107Leu	B:C0596611
.	O

Seventy	O
percent	O
of	O
M.	B:C0026922
leprae	I:C0026922
mutations	B:C0596611
were	O
related	O
to	O
drug	B:C0013203
resistance	I:C0013203
and	O
were	O
isolated	O
from	O
relapsed	O
patients	O
;	O
the	O
likelihood	O
of	O
relapse	O
was	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
confirmed	O
resistance	B:C0013203
mutations	B:C0596611
(	O
OR	O
range	O
20.1	O
-	O
88.7	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Five	O
of	O
these	O
relapsed	O
patients	O
received	O
dapsone	B:C0010980
monotherapy	B:C0087111
as	O
a	O
primary	O
treatment	B:C0087111
.	O

In	O
summary	O
,	O
the	O
current	O
study	B:C2603343
calls	O
attention	O
to	O
M.	B:C0026922
leprae	I:C0026922
resistance	B:C0013203
in	O
Colombia	B:C3245499
,	O
especially	O
the	O
significant	O
association	O
between	O
confirmed	O
resistance	B:C0013203
mutations	B:C0596611
and	O
relapse	O
in	O
leprosy	B:C0023343
patients	O
.	O

A	O
high	O
frequency	O
of	O
drug	B:C0017337
resistance	I:C0017337
determining	I:C0017337
region	I:C0017337
mutations	B:C0596611
for	O
rifampicin	B:C0035608
was	O
seen	O
in	O
a	O
region	B:C0017446
where	O
dapsone	B:C0010980
monotherapy	B:C0087111
was	O
used	O
extensively	O
.	O

